Expression of Programmed Cell Death-1 (PD-1) and Its Ligand (PD-L1) in Breast Cancers and Its Association with Clinicopathological Parameters: A Study from North India
Introduction Cancer immunotherapy targeting the programmed cell death ligand 1 (PD-L1) and programmed cell death-1 (PD-1) axis has revolutionized cancer therapy. PD-L1 also serves as a predictive marker for such therapy. To assess the potential of such therapy in any cancer, the positivity of PD-1 a...
Guardado en:
Autores principales: | Anoushika Mehan, Michael Leonard Anthony, Pranoy Paul, Anjum Syed, Nilotpal Chowdhury, Shalinee Rao, Nuzhat Hussain, Bina Ravi |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3e7680abb3dd43d2ad4124ebd1b85cd7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1/PD-L1 pathway
por: Chunyi Shen, et al.
Publicado: (2021) -
D-1 / PD-L1 EXPRESSION IN INVASIVE BREAST CARCINOMA / CANCER
por: Sammeen Salim, et al.
Publicado: (2021) -
Inhibition of PI3Kδ Differentially Regulates Poly I:C– and Human Metapneumovirus–Induced PD–L1 and PD–L2 Expression in Human Bronchial Epithelial Cells
por: Tomohiro Ogawa, et al.
Publicado: (2021) -
Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave
por: Xinfang Yu, et al.
Publicado: (2021) -
Clinical significance of programmed death 1 ligand-1 (CD274/PD-L1) and intra-tumoral CD8+ T-cell infiltration in stage II–III colorectal cancer
por: Chih-Yang Huang, et al.
Publicado: (2018)